
Outrun Therapeutics has selected an E6AP inhibitor strategy as its lead programme for treating HPV positive head and neck cancer. …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

